Off-Label Use of Ketamine for the Treatment of Patients With Mood Disorders
Patients with mood disorders that are refractory to standard therapies may be candidates for the off-label use of ketamine. According to a report published in JAMA, although ketamine has been approved by the US Food and Drug Administration for use as an anesthetic for more than 45 years, concerns persist regarding the safety of repeated ketamine dosing.
Efficacy of Ketamine in the Treatment of Substance Use Disorders: A Systematic Review
Despite advances in behavioral and pharmacotherapy interventions, substance use disorders (SUDs) are frequently refractory to treatment. Glutamatergic dysregulation has received increasing attention as one common neuropathology across multiple substances of abuse.
Content of external articles is copyright/owned by their respective sources.